Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Aclaris takes a step towards an oral rheumatoid arthritis therapy.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.